Risk of complications related to IBD in patients with versus without eosinophilic oesophagitis
| HR (95% CI) | P values | aHR (95% CI) * | P values | |
| Crohn’s disease | ||||
| Corticosteroids † | 1.19 (1.11 to 1.28) | <0.01 | 1.14 (1.06 to 1.22) | <0.01 |
| Biological therapy | 1.05 (0.91 to 1.22) | 0.48 | 0.77 (0.66 to 0.89) | <0.01 |
| Hospitalisation | 1.02 (0.91 to 1.14) | 0.75 | 0.95 (0.85 to 1.06) | 0.36 |
| Abdominal surgery | 0.80 (0.67 to 0.97) | 0.02 | 0.80 (0.66 to 0.96) | 0.02 |
| Composite | 1.14 (1.07 to 1.22) | <0.01 | 1.09 (1.02 to 1.16) | 0.01 |
| UC | ||||
| Corticosteroids † | 1.15 (1.04 to 1.27) | <0.01 | 1.10 (1.00 to 1.22) | <0.05 |
| Biological therapy | 1.06 (0.68 to 1.67) | 0.78 | 0.70 (0.45 to 1.11) | 0.13 |
| Hospitalisation | 1.13 (0.93 to 1.37) | 0.23 | 1.18 (0.97 to 1.44) | 0.10 |
| Abdominal surgery | 0.61 (0.40 to 0.94) | 0.02 | 0.69 (0.45 to 1.06) | 0.10 |
| Composite | 1.12 (1.02 to 1.23) | 0.02 | 1.10 (1.00 to 1.21) | 0.04 |
*Multivariable regression models were adjusted for age, sex, geographic region and baseline surrogate markers of IBD severity (systemic corticosteroid use, biological therapy, IBD-related hospitalisation and intestinal resection).
†Systemic corticosteroids for IBD.
aHR, adjusted HR; EoO, eosinophilic oesophagitis.